



News Release

Suven Revenue growth at 7.8% while PAT is down by 20% for the half year ended Sept, 2014

HYDERABAD, INDIA (14 Nov' 2014) – SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, today announced its Un-audited financial results for the quarter ended 30th September 2014. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 14th Nov' 2014 at Hyderabad.

Financial Highlights for the 2nd Quarter ended September' 2014:

Growth in revenue Rs 1412 Mn vs Rs 1515 Mn - down by 6.8%
Growth in PAT Rs 248 Mn vs. Rs 455 Mn - down by 45%
Growth in EBIDTA Rs 398 Mn vs. Rs 715 Mn - down by 44 %

Financial Highlights for the Half year ended September' 2014:

Growth in revenue Rs 2839 Mn vs Rs 2633 Mn - up by 7.8%
Growth in PAT Rs 596 Mn vs. Rs 753 Mn - down by 20%
Growth in EBIDTA Rs 988 Mn vs. Rs 1177 Mn - down by 16%

PAT for the current quarter was reduced by Rs. 32.2 Mn & for the Half year reduced by Rs.72.8 Mn due to charge of additional depreciation computed as per Schedule II of the Companies Act 2013 effective April 1, 2014, shown as exceptional item in Profit & Loss Account. If the similar provisions of same quarter of previous years followed the PAT for this quarter would have been higher by Rs. 32.2 Mn to Rs 280.5 million and PAT for the half year would have been higher by Rs.72.8 million to Rs 668.5 million

Lower revenue and PAT during this quarter compared to the same quarter last year is due to the absence of pre-launch supplies of intermediates for 3 of the NCE's which were done last year. The repeat order for these supplies may happen after a gap of 12-18 months.

Suven's major thrust on innovative R&D in Drug Discovery continues with a spending of Rs 259 Mn (7.02% on revenue) for the half year ended Sept' 2014.

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;